MindMed (MNMD)

• Market cap: $476M
• 1 day: -0.94%
• 5 days: 4.65%
• 1 month: 7.69%
• 3 months: -13.93%
• 6 months: -2.33%
• Year to date: -16.45%
• 1 year: -30.23%
• 5 years: -89.55%
• 10 years: -89.55%
• Sector: Healthcare
• Industry: Biotechnology

About: Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).

Employees: 74

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

196% more call options, than puts

Call options by funds: $14.5M | Put options by funds: $4.88M

88% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 32

80% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 20

50% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 3 (+1) [Q4]

9% more funds holding

Funds holding: 156 [Q3] → 170 (+14) [Q4]

3% more capital invested

Capital invested by funds: $282M [Q3] → $289M (+$7.18M) [Q4]

4.24% less ownership

Funds ownership: 60.82% [Q3] → 56.58% (-4.24%) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $16 154% upside
• Avg. target: $36 463% upside
• High target: $55 773% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Baird Joel Beatty 29% 1-year accuracy 11 / 38 met price target	154% upside $16	Outperform Maintained	7 Mar 2025
HC Wainwright & Co. Patrick Trucchio 21% 1-year accuracy 40 / 187 met price target	773% upside $55	Buy Reiterated	7 Mar 2025